000813 Share Price Performance
CN¥4.39
1.25 (39.81%)
Price CN¥4.39
Share PriceCN¥4.39
There's Reason For Concern Over Dezhan Healthcare Company Limited's (SZSE:000813) Massive 34% Price Jump
Dec 10
Dezhan Healthcare Company Limited Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
000813 Community Narratives
There are no narratives available yet.
Dezhan Healthcare Company Limited Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Oct 25, 2025
- Earnings per share (EPS)
- -0.035
- Gross Margin
- 61.48%
- Net Profit Margin
- -19.11%
- Debt/Equity Ratio
- 2.3%
Dezhan Healthcare Company Limited Competitors
Snowflake Analysis
About 000813
- Founded
- 1980
- Employees
- 1054
- CEO
- WebsiteView website
Dezhan Healthcare Company Limited engages in the research and development, manufacture, and sale of cardiovascular and cerebrovascular drugs in the People’s Republic of China. The company offers atorvastatin calcium tablets, amlodipine atorvastatin calcium tablets, trimetazidine hydrochloride capsules, amiodarone hydrochloride tablets, as well as other drugs, including famciclovir tablets, azathioprine tablets, and hydroxyurea tablets and colchicine tablet. It is also involved in the provision of biological peptides, industrial hemp, and medical service business; and food and beverages, and cosmetics under the Hanhui, Xiao Lan, Ruyin Fangxing, and Ma Yuansu brands. The company was founded in 1980 and is based in Beijing, the People’s Republic of China.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
Chinese Market Performance
- 7 Days: 0.6%
- 3 Months: 18.4%
- 1 Year: 24.1%
- Year to Date: 26.2%
In the last week, the market has stayed flat, however the Materials sector stood out, gaining 3.3%. More promisingly, the market is up 24% over the past year. Looking forward, earnings are forecast to grow by 27% annually. Market details ›